Breast imaging technologies market seen reaching $8.13 billion by 2030

Allied Market Research says the global breast imaging technologies market will grow from $3.73 billion in 2020 to $8.13 billion by 2030. The report points to rising breast cancer prevalence, early-diagnosis demand and healthcare investment as key growth drivers, while North America leads today and Asia-Pacific is set to grow fastest.

Why it matters: - Breast imaging technologies are central to early breast cancer detection, which can affect treatment timing and outcomes. - Allied Market Research projects the market will nearly double by 2030, signaling continued investment in screening and diagnostic tools. - The report also points to a market shift toward automated and non-ionizing technologies.

What happened: - Allied Market Research published a report on the global breast imaging technologies market on June 10, 2026. - The market was valued at USD 3.73 billion in 2020 and is forecast to reach USD 8.13 billion by 2030. - The report projects an 8.1% CAGR from 2020 to 2027. - The study covers ionizing and non-ionizing breast imaging technologies.

The details: - The report examines top investment pockets, winning strategies, drivers, opportunities, market sizing, competitive dynamics and market trends. - The report says rising breast cancer prevalence, stronger demand for early diagnosis and higher public and private healthcare investment are driving growth. - High detection costs and strict regulatory approval processes are restraining growth. - Technological advances in medical devices, new screening technologies and demand for early diagnosis are creating additional opportunities. - The ionizing breast imaging segment held nearly two-thirds of the global market in 2020. - Ionizing breast imaging is expected to remain the dominant revenue segment through the forecast period. - The non-ionizing breast imaging segment is projected to post the fastest CAGR at 8.7% from 2021 to 2030. - The non-ionizing segment is being boosted by rising breast cancer incidence among women and automated ultrasound systems. - North America held more than one-third of global revenue in 2020 and is expected to keep its lead by 2030. - Asia-Pacific is projected to grow at the fastest pace, with a CAGR of 9.2% during the forecast period. - The report also includes regional coverage for Europe and LAMEA. - The company lists Canon, Fluidigm, Fujifilm, GE, Hologic, Koning, Philips, Siemens, Smart Breast and Sonocine among top players. - The report says the market was disrupted by the Covid-19 pandemic as hospitals shifted resources to Covid care and many elective procedures were delayed. - A study cited in the report found breast imaging modalities fell 41.7% to 64.4% from April to July 2020. - The report offers a sample PDF and a purchase inquiry page for readers who want more information: the sample report and purchase inquiry.

Between the lines: - The forecast suggests breast imaging demand is tied not just to cancer incidence, but also to screening access, reimbursement pressure and regulatory speed. - North America’s lead appears rooted in approval activity and healthcare technology development, while Asia-Pacific’s growth points to expanding screening adoption. - The pandemic disruption showed how quickly non-urgent imaging volumes can fall when hospital capacity is redirected.

What’s next: - The non-ionizing segment is positioned to gain share if automated ultrasound and other lower-risk screening tools continue to improve. - Market growth will likely depend on how quickly manufacturers, providers and regulators can balance cost, access and approval requirements. - Regional expansion in Asia-Pacific may become a key growth engine as early-diagnosis demand increases.